Although financial terms weren’t disclosed, Norstella estimates that it is now a $5 billion player in the market, the company said in a Nov. 1 press release. The acquisition was first announced in June.
Citeline, which was formerly known as Pharma Intelligence, joins Norstella’s other four constituent groups: pharma commercial intelligence provider Evaluate, market access specialist MMIT, healthcare data analytics software provider Panalgo and market access consultancy The Dedham Group.
We’re looking for agile, growth-oriented team players who are passionate about client success and helping clients bring life-saving therapies to market quicker—and help patients in need.
Work with us
Have questions about Norstella or its brands? Or do you want to know more about how to solve your challenges at each stage of the drug life cycle?
We want to hear from you